Edition:
United States

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

10.35USD
15 Dec 2017
Change (% chg)

$0.17 (+1.67%)
Prev Close
$10.18
Open
$10.19
Day's High
$10.47
Day's Low
$10.19
Volume
336,399
Avg. Vol
56,593
52-wk High
$54.70
52-wk Low
$10.06

Chart for

About

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic... (more)

Overall

Beta: 1.70
Market Cap(Mil.): $138.00
Shares Outstanding(Mil.): 13.33
Dividend: 10.55
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Merrimack Pharmaceuticals Files For Mixed Shelf Of Upto $150 Mln

* MERRIMACK PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text :[http://bit.ly/2yGsbJv] Further company coverage:

Dec 15 2017

BRIEF-Merrimack reports Q3 loss per share from continuing operations $0.40

* Merrimack Pharmaceuticals Inc - Qtrly loss per share from continuing operations $0.40

Nov 08 2017

BRIEF-Merrimack receives orphan drug designation for MM-121 for the treatment of type of lung cancer

* Merrimack receives orphan drug designation for MM-121 for the treatment of heregulin positive non-small cell lung cancer

Oct 30 2017

BRIEF-Merrimack commences tender offer for outstanding 4.50 pct convertible senior notes

* Merrimack commences tender offer for any and all of its outstanding 4.50 pct convertible senior notes due 2020

Oct 13 2017

BRIEF-Merrimack announces settlement of convertible note litigation

* Merrimack announces settlement of convertible note litigation

Oct 10 2017

BRIEF-Merrimack announces date of one-for-ten reverse stock split

* Merrimack announces date of one-for-ten reverse stock split

Aug 31 2017

BRIEF-Merrimack Pharmaceuticals names Jean Franchi CFO

* Merrimack Pharmaceuticals Inc - ‍appointment of Jean M. Franchi as chief financial officer, effective August 21, 2017​ Source text for Eikon: Further company coverage:

Aug 14 2017

BRIEF-Merrimack reports Q2 loss per share $0.22

* Merrimack - continues to believe cash, cash equivalents as of june 30, potential milestone payments, to be sufficient to fund operations into H2 2019​ Source text for Eikon: Further company coverage:

Aug 09 2017

BRIEF-Merrimack appoints Thomas Needham as chief business officer

* Merrimack appoints Thomas Needham as chief business officer Source text for Eikon: Further company coverage:

Jul 24 2017

BRIEF-Merrimack announces completion of enrollment in phase 2 carrie study of mm-141

* Merrimack announces completion of enrollment in phase 2 carrie study of mm-141; data expected in first half of 2018 Source text for Eikon: Further company coverage:

Jun 19 2017

Competitors

Earnings vs. Estimates